CD274 and neoplasm: In addition, we also found that emodin plus anti-PD-L1 (2.5 mg/kg every 3 days) led to a smaller tumor size and tumor volume than anti-PD-L1 (5 mg/kg every 3 days) monotherapy, suggesting that the combination of emodin and anti-PD-L1 has great potential to enhance anti-tumor efficacy and reduce dose-related anti-PD-L1 toxicity.